The macroeconomic burden of hepatitis C and the economic benefit of accelerated investments in China
Bibliographic Data
| ID | 15377912 |
|---|---|
| Authors | Yun Bao (0009-0003-2534-0079, Renji Hospital, corresponding author), Ying Chen (0000-0002-4780-4642, Shanghai Chest Hospital), Jin Huajie (0000-0002-3872-3998, King's College London), Huajie Jin, Chi Zhang (0000-0003-0034-843X, Renji Hospital), Lingli Zhang (0000-0003-1407-8098), Bin Wu (0000-0002-7568-1993) |
| Year | 2025 |
| Volume | 25 |
| Issue | 1 |
| Pages | 1743-1743 |
| Publication date | 2025-05-13 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMC Public Health (JOURNAL) |
| Journal identifiers | ISSN: 1471-2458 • E-ISSN: 1471-2458 |
| Publisher | BioMed Central (PUBLISHER • GB) |
| DOI | 10.1186/s12889-025-22853-7 |
| PMID | 40361015 |
| OpenAlex | W4410333266 |
| Language | EN |
| References cited | 14 |
Achieving the WHO Global Health Sector Strategy diagnosis and treatment coverage targets by 2030 in China is projected to be cost-effective and result in significant health and economic benefits. The findings underscore the importance of increased investment in hepatitis C elimination efforts in China
Biostatistics · China · Development economics · Economics · Environmental health · Public health · Healthcare Systems and Reforms · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · Medicine · Nursing · Epidemiology · Internal Medicine
| Citation velocity | historical |
|---|---|
| Highly cited | No |